Evidence map›Paper›PMID 35769412›Full record

ArticleNeuro-oncology advances

Epigenetic dysregulation in meningiomas.

Michelle A Wedemeyer, Ivo Muskens, Ben A Strickland, Oscar Aurelio, Vahan Martirosian, Joseph L Wiemels, Daniel J Weisenberger, Kai Wang, Debraj Mukerjee, Suhn K Rhie and 1 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Neuro-oncology advances. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.8field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Michelle A WedemeyerDepartment of Neurosurgery, University of California San Francisco, Benioff Children's Hospitals, San Francisco, California, USA.
Ivo MuskensChildren's Cancer Research Laboratory, Center of Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Ben A StricklandDepartment of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Oscar AurelioDepartment of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Vahan MartirosianBrain Tumor Center, University of Southern California, Los Angeles, California, USA.
Joseph L WiemelsChildren's Cancer Research Laboratory, Center of Genetic Epidemiology, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Daniel J WeisenbergerDepartment of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Kai WangDepartment of Pathology and Laboratory Medicine, Children's Hospital of Philadelphia Research Institute, Philadelphia, Pennsylvania, USA.ORCID https://orcid.org/0000-0002-5585-982X
Debraj MukerjeeDepartment of Neurosurgery, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
Suhn K RhieDepartment of Biochemistry and Molecular Medicine, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.
Gabriel ZadaDepartment of Neurosurgery, Keck School of Medicine, University of Southern California, Los Angeles, California, USA.ORCID https://orcid.org/0000-0001-5821-902X
University of Southern California · USChildren's Hospital of Philadelphia · USJohns Hopkins University · USUniversity of California, San Francisco · US

Funding

Mentored Career DevelopmentKL2TR001854 · NCATS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI Elizabeth Rhea Erwin Burner, Amy Elizabeth West · 2016 to 2026
$9.0M
Identification and Clinical Validation of Key Transcription Factor Isoforms Linked to Breast and Prostate Cancer Subgroups using Epigenetic TraitsK01CA229995 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2018 to 2020
$637k
Identifying epigenetic states of TADs and targeting using epigenome editingR21HG011506 · NHGRI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2021 to 2023
$619k
USC Neurosurgery Research Education Training ProgramR25NS099008 · NINDS · UNIVERSITY OF SOUTHERN CALIFORNIA · PI MACK, WILLIAM J · 2017 to 2023
$516k
Mapping regulatory elements and chromatin structures in prostate tumor subtypes at single nucleosome resolutionR21CA264637 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2021 to 2022
$420k
Reversing molecular cancer phenotypes by targeting epigenetic alterations in prostate cancerR21CA260082 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI RHIE, SUHN KYONG · 2021 to 2021
$386k
NINDS NIH HHS R25 NS099008
6 · The paper itself

Abstract

Background: Meningiomas are the most common primary brain tumor. Though typically benign with a low mutational burden, tumors with benign histology may behave aggressively and there are no proven chemotherapies. Although DNA methylation patterns distinguish subgroups of meningiomas and have higher predictive value for tumor behavior than histologic classification, little is known about differences in DNA methylation between meningiomas and surrounding normal dura tissue. Methods: Whole-exome sequencing and methylation array profiling were performed on 12 dura/meningioma pairs (11 WHO grade I and 1 WHO grade II). Single-nucleotide polymorphism (SNP) genotyping and methylation array profiling were performed on an additional 19 meningiomas (9 WHO grade I, 5 WHO grade II, 4 WHO grade III). Results: Using multimodal studies of meningioma/dura pairs, we identified 4 distinct DNA methylation patterns. Diffuse DNA hypomethylation of malignant meningiomas readily facilitated their identification from lower-grade tumors by unsupervised clustering. All clusters and 12/12 meningioma-dura pairs exhibited hypomethylation of the gene promoters of a module associated with the craniofacial patterning transcription factor FOXC1 and its upstream lncRNA FOXCUT. Furthermore, we identified an epigenetic continuum of increasing hypermethylation of polycomb repressive complex target promoters with increasing histopathologic grade. Conclusion: These findings support future investigations of the role of epigenetic dysregulation of FOXC1 and cranial patterning genes in meningioma formation as well as studies of the utility of polycomb inhibitors for the treatment of malignant meningiomas.

Indexed as

epigeneticsFOXC1malignant transformationmeningioma

Identifiers

PMID35769412
PMCPMC9234763
OpenAlexW4281708157

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.